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Abstract
Background: Human cerebral spinal fluid (CSF) is known to be a rich source of small molecule biomarkers for
neurological and neurodegenerative diseases. In 2007, we conducted a comprehensive metabolomic study and
performed a detailed literature review on metabolites that could be detected (via metabolomics or other
techniques) in CSF. A total of 308 detectable metabolites were identified, of which only 23% were shown to be
routinely identifiable or quantifiable with the metabolomics technologies available at that time. The continuing
advancement in analytical technologies along with the growing interest in CSF metabolomics has led us to re-visit
the human CSF metabolome and to re-assess both its size and the level of coverage than can be achieved with
today’s technologies.
Methods: We used five analytical platforms, including nuclear magnetic resonance (NMR), gas chromatography-
mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), direct flow injection-mass
spectrometry (DFI-MS/MS) and inductively coupled plasma - mass spectrometry (ICP-MS) to perform quantitative
metabolomics on multiple human CSF samples. This experimental work was complemented with an extensive
literature review to acquire additional information on reported CSF compounds, their concentrations and their
disease associations.
Results: NMR, GC-MS and LC-MS methods allowed the identification and quantification of 70 CSF metabolites (as
previously reported). DFI-MS/MS allowed the quantification of 78 metabolites (6 acylcarnitines, 13 amino acids,
hexose, 42 phosphatidylcholines, 2 lyso-phosphatidylcholines and 14 sphingolipids), while ICP-MS provided
quantitative results for 33 metal ions in CSF. Literature analysis led to the identification of 57 more metabolites. In
total, 476 compounds have now been confirmed to exist in human CSF.
Conclusions: The use of improved metabolomic and other analytical techniques has led to a 54% increase in the
known size of the human CSF metabolome over the past 5 years. Commonly available metabolomic methods,
when combined, can now routinely identify and quantify 36% of the ‘detectable’ human CSF metabolome. Our
experimental works measured 78 new metabolites that, as per our knowledge, have not been reported to be
present in human CSF. An updated CSF metabolome database containing the complete set of 476 human CSF
compounds, their concentrations, related literature references and links to their known disease associations is freely
available at the CSF metabolome database.
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Background
There is a growing need among the metabolomics and
clinical communities to develop comprehensive, centra-
lized reference resources for clinically important biofluids
such as cerebrospinal fluid, blood, urine and saliva. In
this regard, we have undertaken the task to systematically
characterize each of these biofluids as part of the human
metabolome project [1]. The first biofluid we studied in
detail, in 2007, was human cerebrospinal fluid (CSF) [2].
Although CSF is not an easily accessible biofluid, its rela-
tive metabolic simplicity and potential importance to
central nervous system diseases makes it particularly
important in biomedical research and clinical chemistry
[2]. Since the composition of CSF is directly dependent
upon metabolite production rates in the brain [3], analy-
sis of the CSF metabolome can potentially offer biochem-
ical insights into central nervous system disorders, such
as brain injury [4], Alzheimer’s disease [5], Parkinson’s
disease [6] and multiple sclerosis [7]. Indeed, in the five
years since our initial ‘CSF metabolome’ study was com-
pleted the CSF metabolome database [8] has been used
to facilitate a wide range of metabolomic studies on cen-
tral nervous system diseases, including multiple sclerosis
[9], brain cancer [10] and amyotrophic lateral sclerosis
[11].
At the time it was first published, the CSF metabolome
database consisted of a total of 308 detectable metabo-
lites, with extensive information on compound names,
structures, identifiers, concentrations, related literature
references and links to known disease associations. In
that CSF study [2], we also showed that the metabolomic
technologies available at that time were able to detect
and quantify only about 23% of the known or detectable
CSF compounds. Since that time, continuing advances in
the analytical technologies for metabolomics (including
improvements to instrumentation sensitivity, enhanced
separation capacity, better software and more compound
standards) have occurred. This technical improvement,
along with the growing interest in the CSF metabolome
in clinical communities has led us to re-visit the human
CSF metabolome. In particular we wanted to find out if
these improved technologies could lead to a substantive
improvement to the level of CSF metabolite coverage
achievable by standard metabolomic technologies. We
also wanted to determine if new, or previously unidenti-
fied, CSF metabolites had been reported in the literature
or could be discovered using these enhanced metabolo-
mics platforms. Finally, we wanted to update the CSF
metabolome database so that it contained the latest infor-
mation on all known or detectable CSF metabolites, their
concentrations, the latest references and their disease
associations.
Here we wish to report the results of this work,
including the use of five different metabolomic
platforms (nuclear magnetic resonance (NMR), gas
chromatography-mass spectrometry (GC-MS), liquid
chromatography-mass spectrometry (LC-MS), direct
flow injection-mass spectrometry (DFI-MS/MS) and
inductively coupled plasma-mass spectrometry (ICP-
MS)) to characterize multiple CSF samples as well as an
extensive literature review (covering the period from
2008 to 2011) aimed at identifying and tabulating new
(or previously unidentified) CSF metabolites along with
new or updated CSF metabolite biomarkers. All of these
data, along with their concentrations, related literature
references and links to their known disease associations
are freely available at the CSF metabolome database [8].
Materials and methods
Cerebral spinal fluid samples
Lumbar CSF samples were collected from patients
screened for meningitis in accordance with guidelines
and consent protocols established by the University of
Alberta Research Ethics Board [2] and conforming to the
Declaration of Helsinki principles. Only a small portion
(<5%) were shown to have meningitis, suggesting that the
CSF samples were from mostly neurologically normal
individuals.
A more detailed list describing the patient population is
shown in Table 1. The typical volume of each CSF samples
was 0.5 to 1.0 ml. CSF samples were placed in a freezer for
long-term storage at -80°C. All CSF samples were thawed
on ice for approximately 2 h before use. A total of seven
samples were used for the analyses described below.
NMR, GC-MS and LC-MS compound identification and
quantification
Identical procedures using identical instruments, as
described in [2], were employed to process and character-
ize metabolites from the CSF samples collected above.
More specifically, all 1H-NMR spectra were collected on
500 μl CSF samples at 25°C (via the first transient of the
tnnoesy-presaturation pulse sequence) using a 500 MHz
Inova (Varian Inc., Palo Alto, CA, USA) spectrometer
equipped with a 5 mm Z-gradient PFG Varian cold-probe.
All 1H-NMR spectra were baseline corrected and analyzed
using the Chenomx NMR Suite Professional software
package version 6.1 (Chenomx Inc., Edmonton, AB,
Canada). All GC-MS data were acquired on an HP 6890/




Age Adult (18 to 40 years old)
Race White
Disease Screened for meningitis; only a small portion (<5%)
were shown to have meningitis
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5975 GC/MS equipped with a DB-5 column. N-methyl-N-
(trimethylsilyl) trifluoroacetamide (MSTFA) derivatized
extracts were prepared from 200 μl of CSF using standard
methods [2]. Samples were run using full scan at a mass
range of 50 to 500 m/z, with a 55 minute run time using a
starting temperature of 70°C and a final temperature of
350°C. Trimethylsilated metabolites were identified using
the AMDIS (automated mass spectral deconvolution and
identification system) software package [12] in conjunction
with the 2008 National Institute of Standards and Tech-
nology (NIST) library [13], and quantified using external
multi-point calibration curves. For the LC-MS studies,
CSF samples were pooled and analyzed using a Bruker
Daltonics 9.4T Apex-Qe FT-ICR mass spectrometer
equipped with a Waters ultra-performance liquid chroma-
tography (UPLC) system. Spectra were collected in both
positive and negative ion modes. Metabolites were identi-
fied and confirmed by high resolution Fourier transform
mass spectrometry (FTMS by comparing their parent ion
and fragment ion masses to known masses or fragment
ion spectra from the Human Metabolome Database [14].
DFI-MS/MS compound identification and quantification
In addition to characterizing CSF using NMR, GC-MS
and LC-FTMS, we also employed a targeted quantitative
metabolomics approach using direct flow injection mass
spectrometry (AbsoluteIDQ™ kit). The kit is a commer-
cially available assay from Biocrates Life Sciences AG
(Innsbruck, Austria), and it was originally validated for
plasma samples. Recently, the kit has been optimized for
the analysis of human CSF [15] and urine samples. This
kit assay, in combination with a 4000 QTrap (Applied
Biosystems/MDS Sciex, Concord, Ontario, Canada)
mass spectrometer, was used to identify and quantify of
a large number of endogenous metabolites, including
amino acids, acylcarnitines, glycerophospholipids, sphin-
golipids and sugars. The method combines the derivati-
zation and extraction of analytes with the selective
mass-spectrometric detection using multiple reaction
monitoring (MRM) pairs. Isotope-labeled internal stan-
dards are integrated into a kit plate filter for metabolite
quantification.
The AbsoluteIDQ™ kit contains a 96 deep-well plate
with a filter plate attached with sealing tape, as well as
reagents and solvents used to prepare the plate assay. The
first eight wells in each kit are used for standardization
and quality control. A straightforward sample preparation
step was used for the assay, as described in the kit’s user
manual. CSF samples were left to thaw on ice, and then
vortexed and centrifuged at 13,000 × g. A total of 30 μl of
supernatant from each CSF sample was loaded on a filter
paper placed on top of the kit plate and dried in a stream
of nitrogen. Subsequently, 20 μl of a 5% solution of phe-
nyl-isothiocyanate was added for derivatization. After
incubation, the filter spots were dried again using an eva-
porator. Extraction of the metabolites was then achieved
by adding 300 μl methanol containing 5 mM ammonium
acetate. The extracts were obtained by centrifugation into
the lower 96-deep well plate, followed by a dilution step
with 600 μl of the kit’s mass spectrometry running solvent.
The extracts were analyzed using a 4000 QTrap (Applied
Biosystems/MDS Sciex) mass spectrometer. A standard
flow injection protocol consisting of two 20 μl injections
(one for the positive and one for the negative ion detection
mode) was applied for all measurements. MRM detection
was used for quantification. MetIQ software, which is pro-
prietary to Biocrates and included in the kit, was used to
control the entire assay workflow. This included sample
registration to automated calculation of metabolite con-
centrations to the export of data into other data analysis
programs.
Multi-element analysis using ICP-MS
For elemental (primarily metal) analysis by ICP-MS, seven
CSF samples were processed as described previously [16].
In particular, CSF samples were sonicated in an ultrasound
water bath for 10 minutes in order to obtain a homoge-
neous dispersion. The sample was then diluted with 2%
HNO3. Elemental concentrations were determined on a
Perkin-Elmer Sciex Elan 6000 quadrupole ICP-MS operat-
ing in a dual detector mode (Santa Clara, California, USA).
Blank subtraction was applied after internal standard cor-
rection. A four point calibration curve was used to quan-
tify compounds (0, 0.025, 0.050, and 0.100 ppm for Na; 0,
0.25, 0.50, and 1.00 ppm for Ca, Mg, Fe, K; 0, 0.005, 0.010,
and 0.020 ppm for the remaining elements). The sample
uptake rate was approximately 1 ml/minute with 35
sweeps per reading using one reading per replicate and
three replicates. Dwell times were 10 to 20 ms for all ele-
ments with the exception of As (which was 100 ms). The
relative standard deviation (2s level) for As, Ni, Pb, and
Zn was between 5 and 10%. The accuracy of the ICP-MS
analytical protocol was periodically evaluated via the ana-
lysis of certified reference standard materials (whole rock
powders) BE-N and DR-N available from the SARM
laboratory at the CRPG (Centre de Recherches Pétrogra-
phiques et Géologiques).
Literature survey of CSF metabolites
In addition to the experimental analysis of the CSF meta-
bolome described above, a comprehensive literature review,
covering the past 4 years (2008 to 2011) was performed to
look at known or newly discovered CSF metabolites and
metabolite concentrations. An in-house text-mining tool,
which was originally developed for the Human Metabo-
lome Database [14], was used to facilitate the literature sur-
vey. This program generated a hyperlinked list of abstracts
and papers from PubMed containing relevant information
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about CSF metabolites and CSF concentration data. Key-
words used for this literature search included terms such
as ‘CSF’, ‘cerebrospinal fluid’, ‘human’, ‘concentration’,
‘quantification’ and the names of the metabolites in the
Human Metabolome Database. From the resulting 106
papers and abstracts, we manually extracted metabolite
information (metabolite identities, concentrations, asso-
ciated disease states, and so on) and entered the data into
our CSF metabolome database.
Results and discussion
NMR, GC-MS and LC-MS compound identification and
quantification
A total of 53 metabolites were identified (47 quantified) by
NMR, 41 metabolites were identified (15 quantified) by
GC-MS, and LC-MS permitted the identification of 17
metabolites. A total of 70 non-redundant CSF metabolites
were identified (62 quantified) using these three platforms.
No additional metabolites beyond those originally reported
in [2] were identified. No doubt the use of more modern
equipment might have improved the situation, but cer-
tainly when considering NMR as a metabolomic platform,
CSF spectra appear to be fully determined and fully
assigned. A typical 500 MHz 1H-NMR spectrum and high
resolution GC-MS total ion chromatogram are shown in
Figures 1 and 2, respectively.
DFI-MS/MS compound identification and quantification
The Biocrates AbsoluteIDQ™ kit permits the measure-
ment of 162 metabolites (41 acylcarnitines, 14 amino
acids, hexose, 76 phospatidylcholines (PCs), 15 lyso-phos-
phatidylcholines and 15 sphingolipids). From these 162
potentially detectable metabolites, quantitative results
were obtained for 78 metabolites (6 acylcarnitines, 13
amino acids, hexose, 42 PCs, 2 lyso-phosphatidylcholines
and 14 sphingolipids). These results are summarized in
Figure 1 Typical 500 MHz 1H-NMR spectrum of human cerebrospinal fluid. Numbers indicate the following metabolites: 1, DSS; 2,
imidazole; 3, 2-hydroxybutyric acid; 4, 2-hydroxyisovaleric acid; 5, 2-oxoisovaleric acid; 6, 3-hydroxybutyric acid; 7, 3-hydroxyisobutyric acid; 8, 3-
hydroxyisovaleric acid; 9, acetic acid; 10, acetoacetic acid; 11, acetone; 12, L-glutamine; 13, pyruvic acid; 14, L-glutamic acid; 15, citric acid; 16,
creatinine; 17, creatine; 18, D-glucose; 19, L-lactic acid; 20, myo-inositol; 21, D-fructose; 22, formic acid; 23, L-histidine; 24, L-tyrosine; 25, methanol;
26, glycerol.
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Table 2 and typical direct flow injection (DFI) spectra in
both positive and negative modes are shown in Figure 3.
The other 84 metabolites that were assayed were below
the limit of detection. This result is in agreement with a
previous study conducted by Biocrates (Application Note
1003-1 [15]) for pooled human CSF samples that reported
a total of 65 quantified metabolites (5 acylcarnitines, 14
amino acids, hexose, 35 PCs and 10 sphingolipids).
Of the 78 metabolites quantified by DFI-MS/MS, 11
compounds (10 amino acids and hexose/glucose) were
also measurable using NMR and/or GC-MS. The mea-
sured concentrations for these common compounds on all
three platforms showed very good agreement (within 15 to
30% of each other). More importantly, the DFI-MS/MS
method provided quantitative data on 67 unique com-
pounds that GC-MS, LC-MS and NMR methods could
not detect. It is important to note, however, that DFI-MS/
MS generates phospholipid data (PCs) that only identifies
PCs by their total acyl/alkyl chain content (for example,
PC aa 38:4) rather than their precise chemical structure.
These 42 PC ‘species’ along with their concentrations are
entered in our CSF metabolome database. In addition,
each PC species is linked to a list of the most probable PC
structures (586 in total) based on the known fatty acid
compositions in humans.
Multi-element analysis using ICP-MS
Trace metals are known to play an important role in
enzyme function and a wide number of neurodegenera-
tive diseases like Alzheimer’s disease, Parkinson’s disease
and other related diseases [17]. A new trend in metabolo-
mics (called ‘metallomics’) is evolving wherein trace
metal concentrations of tissues, biofluids and even indivi-
dual cells are measured. It is essential to measure trace
metal concentrations in tissues and body fluids to be
used as reference values. However, less data are available
for normal or reference values of element concentrations
for CSF samples due to the difficulties in accessing the
samples and low concentrations of elements. In a recent
review the importance of trace metal analysis and the
potential of metal speciation analysis in CSF as a diagnos-
tic tool for better understanding of neurodegenerative
diseases were discussed [18]. An overview of current ana-
lytical techniques (like ICP-MS, inductively coupled
plasma optical emission spectrometry, atomic absorption
spectroscopy) and the results of total concentrations and
Figure 2 Typical GC-MS total ion chromatogram spectrum of human cerebrospinal fluid. Numbers indicate the following metabolites: 1, L-
lactic acid; 2, oxalic acid; 3, L-alanine; 4, glycine; 5, L-valine; 6, urea; 7, glycerol; 8, L-serine; 9, L-threonine/pyroglutamic acid; 10, L-glutamine; 11, L-
phenylalanine; 12, ribitol; 13, L-glutamic acid; 14, citric acid; 15, D-fructose; 16, D-glucose; 17, D-galactose; 18, L-lysine; 19, mannitol; 20, L-tyrosine;
21, myo-inositol.
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Table 2 Concentrations of metabolites in human cerebrospinal fluid samples
Compound name Average (μM) Standard deviation (μM) Literature value (μM)
1,5-Anhydrosorbitola 25 13 18 ± 5
2-Hydroxybutyric acida, b 40 24 35 ± 24
2-Hydroxyisovaleric acida 8 6 7 ± 7
2-Oxoglutaric acida 5 4 9 ± 3
2-Oxoisovaleric acida 6 3 8 ± 7
3-Hydroxybutyric acida 34 31 46 ± 24
3-Hydroxyisobutyric acida 6 3 18 ± 18
3-Hydroxyisovaleric acida 4 2 NA
Acetaminophena 11 6 NA
Acetic acida 58 27 100 ± 30
Acetoacetic acida 12 14 6 ± 6
Acetonea 20 21 67 ± 24
L-Alaninea 46 27 37 ± 7
Cholinea 3 1 8 ± 5
Citric acida 225 96 176 ± 50
Creatinea 44 13 NA
Creatininea 43 12 65 ± 25
Dimethylsulfonea 2 1 11 ± 6
Dimethylaminea 2 1 NA
Formic acida 32 16 NA
D-Fructosea 160 91 240 ± 20
D-Glucosea, c 2,960 1,110 5,390 ± 1,650
L-Glutamic acida 40 52 33 ± 7
L-Glutaminea, c 398 150 444 ± 80
Glycerola, b 28 14 14 ± 3
L-Histidinea, c 15 8 12 ± 2
L-Isoleucinea 7 5 8 ± 3
Isopropyl alcohola 22 56 NA
Lactic acida 1,651 626 1,590 ± 330
L-Leucinea 16 9 19 ± 4
L-Lysinea 29 13 28 ± 8
D-Mannosea 24 13 64 ± 8
Methanola 44 36 NA
L-Methioninea, c 5 4 6 ± 3
Myo-inositola 84 40 133 ± 20
Oxalacetic acida 27 15 7 ± 2
L-Phenyalaninea, c 15 8 18 ± 7
Propylene glycola 33 50 7.3 ± 0.5
Pyroglutamic acida 47 30 41 ± 30
Pyruvic acida 53 42 71 ± 30
L-Serinea, c 38 14 42 ± 15
L-Threoninea, c 28 8 28 ± 5
L-Tryptophana, c 10 5 2 ± 1
L-Tyrosinea 12 9 10 ± 4
L-Valinea 19 13 24 ± 7
Xanthinea 13 7 5 ± 1
4-Aminobutyric acidb <1 <1 0.3 ± 0.1
Adenosineb <1 <1 0.01 ± 0.01
Ascorbic acidb 178 15 164 ± 20
L-Asparagineb 4 2 5 ± 1
L-Aspartic acidb 2 1 3 ± 1
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Table 2 Concentrations of metabolites in human cerebrospinal fluid samples (Continued)
D-Galactoseb 107 45 166 ± 99
Mannitolb 5 2 5 ± 1
Ribitolb 18 5 4 ± 12
Succinic acida, b 47 12 29 ± 5
Thymineb <5 <2 <1
Ureab 3,820 1,600 4,160 ± 1,800
Uric acidb 15 10 16 ± 12
DL-carnitinec 1.9 0.5 4.0 ± 2.0
Acetyl-L-carnitinec 0.322 0.148 NA
Propionyl-L-carnitinec 0.018 0.009 NA
Hydroxypropionylcarnitinec 0.063 0.030 NA
Butyryl-L-carnitinec 0.024 0.007 NA
Valeryl-L-carnitinec 0.013 0.006 NA
Glycineb, c 6.1 1.4 8.2 ± 3.0
L-Argininec 17.9 5.7 20.2 ± 6.3
L-Ornithinec 4.5 2.2 6.0 ± 1.5
L-Prolinec 1.9 1.0 4.0 ± 2.0
SM (OH) C14:1c 0.028 0.004 NA
SM (OH) C16:1c 0.020 0.007 NA
SM (OH) C22:1c 0.034 0.009 NA
SM (OH) C22:2c 0.032 0.008 NA
SM (OH) C24:1c 0.017 0.004 NA
SM C16:0c 0.336 0.109 NA
SM C16:1c 0.040 0.016 NA
SM C18:0c 0.340 0.154 NA
SM C18:1c 0.069 0.026 NA
SM C20:2c 0.003 0.001 NA
SM C24:0c 0.114 0.022 NA
SM C24:1c 0.230 0.113 NA
SM C26:0c 0.007 0.001 NA
SM C26:1c 0.007 0.003 NA
PC aa C30:0c 0.086 0.005 NA
PC aa C30:2c 0.010 0.004 NA
PC aa C32:0c 0.252 0.080 NA
PC aa C32:1c 0.150 0.051 NA
PC aa C32:2c 0.024 0.008 NA
PC aa C34:1c 1.800 0.490 NA
PC aa C34:2c 0.245 0.010 NA
PC aa C34:3c 0.038 0.003 NA
PC aa C36:1c 0.212 0.062 NA
PC aa C36:2c 0.302 0.044 NA
PC aa C36:3c 0.126 0.040 NA
PC aa C36:4c 0.228 0.036 NA
PC aa C36:5c 0.041 0.007 NA
PC aa C38:1c 0.041 0.002 NA
PC aa C38:3c 0.110 0.049 NA
PC aa C38:4c 0.209 0.068 NA
PC aa C38:5c 0.074 0.011 NA
PC aa C38:6c 0.079 0.010 NA
PC aa C40:3c 0.004 0.001 NA
PC aa C40:4c 0.015 0.007 NA
PC aa C40:5c 0.031 0.003 NA
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speciation information for several elements, such as Al,
As, Ca, Cd, Cu, Fe, Mg, Mn, Hg, Pb, Se and Zn, in CSF
were highlighted and summarized in that review [18].
In the present paper, the metal ion composition of
seven CSF samples was measured by using ICP-MS.
ICP-MS is widely regarded as one of the best techniques
for the characterization of the elemental composition of
biological samples. This method was able to provide
quantitative results for 33 metals or trace elements, as
shown in Table 3. These data suggest that CSF is a rea-
sonably rich reservoir of trace metals and that ICP-MS
can be effectively used to identify and quantify a large
number of trace minerals. Furthermore, our experimen-
tal results agree reasonably well with the literature
values for most of the metal ions except for Al, V, Cr,
Ni and As (Table 3). These concentration differences
may be due to methodological or equipment differences
or they may be due to regional differences with regard
to environmental or occupational exposure.
Literature survey of CSF metabolites
Our literature review allowed us to identify another 57
metabolites that had not been previously archived in the
human CSF metabolome database. Furthermore, the lit-
erature review also allowed us to update, correct and add
more than 500 new concentration ranges or averages.
Additionally, dozens of new disease-metabolite associa-
tions were also identified and many older disease-meta-
bolite associations were also updated. A total of 229
disease-metabolite associations are listed in the CSF data-
base. In many cases, multiple concentration values are
given for ‘normal’ conditions, in order to provide the
users/readers with a better estimate of the potential con-
centration variations obtained by different technologies
or laboratories. In general, there is good agreement
between most laboratories and methods.
The human CSF metabolome - then and now
The 2008 version of the human CSF metabolome con-
tained 308 fully identified and quantified metabolites [2].
Of these, 70 compounds (or 23%) were shown to be rou-
tinely identifiable using a combination of NMR, GC-MS
and ultra performance liquid chromatography UPLC-
FTMS. Because of the very hydrophilic nature of CSF, it
was shown that NMR was the most useful metabolomic
platform for characterizing CSF. In 2011, thanks to an
extensive literature review and additional experimental
analyses, we determined that the human CSF metabo-
lome contains at least 476 fully identified and quantified
metabolites. This represents a 54% increase over the
2008 edition of the CSF metabolome. We were also able
to reassess the performance of the previously used
Table 2 Concentrations of metabolites in human cerebrospinal fluid samples (Continued)
PC aa C42:4c 0.004 0.001 NA
PC ae C32:1c 0.022 0.007 NA
PC ae C34:0c 0.018 0.005 NA
PC ae C34:1c 0.085 0.008 NA
PC ae C34:2c 0.062 0.005 NA
PC ae C34:3c 0.011 0.001 NA
PC ae C36:1c 0.032 0.007 NA
PC ae C36:2c 0.024 0.009 NA
PC ae C36:3c 0.017 0.006 NA
PC ae C36:4c 0.024 0.005 NA
PC ae C36:5c 0.032 0.005 NA
PC ae C38:1c 0.009 0.002 NA
PC ae C38:2c 0.013 0.002 NA
PC ae C38:3c 0.009 0.003 NA
PC ae C38:4c 0.020 0.005 NA
PC ae C38:5c 0.025 0.008 NA
PC ae C38:6c 0.014 0.004 NA
PC ae C40:5c 0.006 0.001 NA
PC ae C40:6c 0.018 0.003 NA
PC ae C44:4c 0.013 0.001 NA
PC ae C44:5c 0.024 0.009 NA
lysoPC a C18:0c 0.069 0.019 NA
lysoPC a C20:4c 0.024 0.007 NA
aMetabolites measured by NMR. bMetabolites measured by GC-MS. cMetabolites measured by DFI-MS/MS. aa, diacyl; ae, acyl-alkyl; NA, not available; PC,
phosphatidylcholine; SM, sphingomyelin.
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Figure 3 Typical direct flow injection (DFI) spectra of human cerebrospinal fluid. (a) negative mode, MRM (15 pairs); (b) positive mode,
MRM (175 pairs).
Table 3 Multi-element analysis in cerebral spinal fluid samples using ICP-MS
Compound name Average (μM) Standard deviation (μM) Literature value (μM)
Lithium (Li) 10.383 4.679 NA
Beryllium (Be) 0.045 0.019 NA
Boron (B) 3,587 1,093 NA
Sodium (Na) 109,788 10,048 145,000 ± 8,000
Magnesium (Mg) 954 207 890 ± 340
Aluminum (Al) 109 26 12.1 ± 6.3
Potassium (K) 2,163 274 2,960 ± 340
Calcium (Ca) 1047 520 1,190 ± 170
Titanium (Ti) 0.648 0.168 NA
Vanadium (V) 0.404 0.071 0.003 ± 0.001
Chromium (Cr) 0.247 0.067 0.006 ± 0.003
Iron (Fe) 9.293 1.140 5.57 ± 1.68
Manganese (Mn) 0.149 0.177 0.022 ± 0.031
Nickel (Ni) 0.097 0.109 <0.004
Copper (Cu) 2.253 3.118 1.7 ± 1.4
Zinc (Zn) 0.538 0.847 0.49 ± 0.12
Gallium (Ga) 0.011 0.003 <0.001
Arsenic (As) 0.106 0.010 0.003 ± 0.002
Selenium (Se) 0.320 0.038 0.239 ± 0.166
Rubidium (Rb) 0.499 0.097 0.620 ± 0.127
Strontium (Sr) 1.120 2.481 0.534 ± 0.079
Yttrium (Y) 0.004 0.001 NA
Zirconium (Zr) 0.277 0.086 <0.278
Molybdenum (Mo) 0.034 0.016 0.010 ± 0.009
Ruthenium (Ru) 0.005 0.002 NA
Palladium (Pd) 0.036 0.018 NA
Cesium (Cs) 0.015 0.006 0.0063 ± 0.0023
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metabolomic platforms (NMR, GC-MS, UPLC-MS) as
well as two more metabolomic platforms (DFI-MS/MS
and ICP-MS) with regard to their efficacy in CSF meta-
bolite characterization. Our results indicate that while
essentially no improvements could be achieved using the
older platforms, the addition of these two newer plat-
forms led to significant improvements. In particular,
DFI-MS/MS allowed us to identify and quantify 67 pre-
viously unmeasured compounds while ICP-MS allowed
another 33 trace metals to be identified and quantified.
When combined, the five platforms allowed us to mea-
sure 170 of 469 known CSF metabolites (36%). While the
size of the CSF metabolome continues to grow (approxi-
mately 13% a year), the use of improved metabolomic
technologies is allowing even greater coverage (growing
from 23% to 36%) of the human CSF metabolome. Both
trends (that is, the growth in the size of the known meta-
bolome and the growth in metabolome coverage) are
encouraging as they indicate that even though our knowl-
edge of the CSF metabolome is rapidly expanding, our
ability to characterize it is growing even faster.
Conclusions
The main objective of this study was to advance the fields
of quantitative metabolomics and global metabolic profil-
ing to facilitate future CSF research. The updated CSF
metabolome database currently contains 476 detectable
metabolites. Our experimental works measured 78 new
metabolites that, as per our knowledge, have not been
reported to be present in human CSF. This is not a num-
ber that will remain unchanged. As technology improves,
it is most likely that this number will continue to increase.
However, this current set of 476 metabolites appears to
provide a reasonably complete listing of the compounds
that can be detected and quantified (with today’s technol-
ogy) in the human CSF metabolome.
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